DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 207 filers reported holding DENALI THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.17 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $2,119,000 | +4.3% | 69,030 | 0.0% | 0.01% | +42.9% |
| Q2 2022 | $2,032,000 | -73.3% | 69,030 | -70.8% | 0.01% | -74.1% |
| Q1 2022 | $7,614,000 | -41.8% | 236,688 | -19.4% | 0.03% | -40.0% |
| Q4 2021 | $13,093,000 | -7.1% | 293,554 | +5.1% | 0.04% | -8.2% |
| Q3 2021 | $14,088,000 | -14.4% | 279,254 | +33.2% | 0.05% | -31.9% |
| Q2 2021 | $16,449,000 | +106.2% | 209,698 | +50.1% | 0.07% | +176.9% |
| Q1 2021 | $7,977,000 | -67.2% | 139,698 | -51.9% | 0.03% | -70.5% |
| Q4 2020 | $24,349,000 | +2515.4% | 290,698 | +1018.6% | 0.09% | +1157.1% |
| Q3 2020 | $931,000 | – | 25,988 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 19,462,500 | $339,037,000 | 35.95% |
| Euclidean Capital LLC | 323,749 | $27,117,000 | 5.74% |
| Flagship Pioneering Inc. | 2,730,263 | $228,687,000 | 4.16% |
| Casdin Capital, LLC | 1,310,000 | $109,726,000 | 3.25% |
| A.R.T. Advisors, LLC | 6,173 | $517,000 | 2.39% |
| MARK ASSET MANAGEMENT LP | 172,040 | $14,410,000 | 1.73% |
| Temasek Holdings (Private) Ltd | 4,410,457 | $369,420,000 | 1.59% |
| Integral Health Asset Management, LLC | 57,500 | $4,816,000 | 1.43% |
| GILDER GAGNON HOWE & CO LLC | 3,219,843 | $269,694,000 | 1.34% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 19,365 | $1,622,000 | 0.95% |